Products Lacking Good Subgroup Data Shouldn’t Be Approved, Patient, Medical Groups Tell FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.